THU0091 Differences in the Uveitis versus NON Uveitis Individuals with HLAB27 Positive Spondyloarthritis with Regards to Clinical Characteristics, Disease Activity and Function
Authors: J. Diss, N. Rajan, A. Georgiou, E. Roussou
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Anterior uveitis is an extra-articular manifestation of spondyloarthritis (SpA) <h3>Objectives</h3> To analyze patients data and compare the main musculoskeletal problems as well as clinical characteristics (sacroilitis, enthesitis, psoriasis, night pain, well being), disease activity and function on uveitis vs non uveitis in HLAB27 positive SpA cohort aiming to establish the axial SpA uveitis cohort characteristics. <h3>Methods</h3> SpA patients were asked to complete a questionnaire assessing their disease type, age at diagnosis, clinical presentation, disease-activity (BASDAI score) and functional-indices (BASFI score). Only HLA-B27 positive patients9 responses were analysed, with those reporting an ophthalmological anterior uveitis diagnosis (current or past) compared to those without uveitis. Means and standard errors were calculated. Statistical significance was determined using unpaired t-tests or Pearson9s chi-squared tests. <h3>Results</h3> Of 67 HLA-B27 positive patients, 24 (35.8%) had a history of uveitis (M:F =9:15; mean age, 46.1 ± 3.2 years) and 43 (64.2%) (M:F =20:23; 42.7 ± 2.0 years) did not. All had axial disease. 7/24 (29.1%) uveitis and 11/43 (25.5%) non-uveitis patients also had peripheral SpA (ASAS criteria; p&gt;0.05). No significant differences in the proportions of patients with undifferentiated SpA (6/24 <i>versus</i> 7/43; ESSG criteria), Ankylosing Spondylitis (AS) (13/24 <i>versus</i> 18/43; AS mod. New York Criteria) or psoriatic arthritis (PsA) (5/24 <i>versus</i> 12/43; CASPAR), or of patients with arthritis (5/24 <i>versus</i> 10/43), enthesitis (4/24 <i>versus</i> 6/43), radiographic sacroiliitis (9/24 <i>versus</i> 14/43), or psoriasis (3/24 <i>versus</i> 12/43) were found between the two groups. There were also no differences in night pain (5.54 ± 0.63 <i>versus</i> 5.20 ± 0.46), well-being over the past week (4.7 ± 0.6 <i>versus</i> 4.8 ± 0.4), disease activity (BASDAI, 5.92 ± 0.43 <i>versus</i> 5.80 ± 0.30) or functional limitation (BASFI, 4.51±0.57 <i>versus</i> 4.50 ± 0.43). Mean age at diagnosis was lower (31.7 ± 2.3 <i>versus</i> 36.3 ± 1.9) and the mean disease duration was longer in the uveitis group (15.5 ± 2.3 <i>versus</i> 11.3 ± 1.4) but this was also not significant (p&gt;0.05). Lower back pain and stiffness (n=15 for both; representing 65.2%) was the predominant MSK manifestations of the uveitis positive group, followed by neck pain (13; 56.5%) joint pains (n=12; 52.2%), fatigue (n=10; 43.5%) upper back pain and enthesitis (n=8; 34.2% for both). In the non-uveitis HLAB27+ group lower back pain was also the predominant manifestation (28; 66.7%) followed by fatigue (n=24; 56.1), stiffness (n=23; 54.8%), joint pains (n=23; 54.8%), neck pain (n=19; 45.2) upper back pain (n=18;42.9) and enthesitis (n=17; 40.5%). There was no statistically significant difference between the uveitis and the non uveitis group with regards to their predominant musculoskeletal manifestations. <h3>Conclusions</h3> Uveitis SpA patients are younger at disease presentation and have the diagnosis earlier than the non uveitis ax-SpA group. No other differences have been identified. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2603